Table 1 Protective efficacy of pIPC and IPC treatment in NOD mice followed-up for 29–30 weeks
Weeks | Number of diabetic mice in the pIPC group (n = 24) | Number of diabetic mice in the IPC group (n = 10) | Number of diabetic mice in the control group (n = 28) | pIPC vs control p OR (95% CI) | Protective efficacy of pIPCs (1 – OR) × 100 | IPC vs control p OR (95% CI) | Protective efficacy of IPCs (1 – OR) × 100 |
|---|---|---|---|---|---|---|---|
9 weeks | 0 (0%) | 0 (0%) | 0 (0%) | – | – | – | – |
10 weeks | 0 (0%) | 0 (0%) | 0 (0%) | – | – | – | – |
12 weeks | 0 (0%) | 0 (0%) | 3 (10.7%) | p < 0.14 OR = 0.14 (0.2–1.25) | 86% | p < 0.39 OR = 0.35 (0.04–2.99) | 65% |
14 weeks | 0 (0%) | 0 (0%) | 5 (17.86%)* | p < 0.03 OR = 0.087 (0.01–0.7) | 91.3% | p < 0.19 OR = 0.2 (0.02–1.68) | 80% |
16 weeks | 1 (4.2%) | 0 (0%) | 6 (21.43%) | p < 0.07 OR = 0.22 (0.06–0.83) | 78% | p < 0.13 OR = 0.16 (0.02–1.34) | 84% |
18 weeks | 3 (12.5%)* | 2 (20%) | 9 (32.14%) | p < 0.08 OR = 0.33 (0.13–0.88) | 67% | p < 0.39 OR = 0.6 (0.19–1.88) | 40% |
20 weeks | 4 (16.2%) | 3 (30%)* | 12 (42.86%) | p < 0.039 OR = 0.29 (0.12–0.7) | 71% | p < 0.37 OR =0.62 (0.22–1.73) | 38% |
22 weeks | 5 (20.8%) | 4 (40%) | 14 (50%) | p < 0.02 OR = 0.26 (0.06–1.03) | 74% | p < 0.43 OR =0.69 (0.26–1.87) | 31% |
24 weeks | 6 (25%) | 4 (40%) | 14 (50%) | p < 0.06 OR = 0.33 (0.08–1.24) | 67% | p < 0.43 OR =0.69 (0.26–1.87) | 31% |
26 weeks | 6 (25%) | 4 (40%) | 14 (50%) | p < 0.06 OR = 0.33 (0.08–1.24) | 67% | p < 0.43 OR =0.69 (0.26–1.87) | 31% |
28 weeks | 6 (25%) | 4 (40%) | 17 (60.71%) | p < 0.009 OR = 0.216 (0.05–0.82) | 78.4% | p < 0.22 OR = 0.45 (0.17–1.24) | 55% |
29/30 weeks | 6 (25%) | 4 (40%) | 17 (60.71%) | p < 0.009 OR = 0.216 (0.05–0.82) | 78.4% | p < 0.22 OR = 0.45 (0.17–1.24) | 55% |